Not recommended for thromboprophylaxis in patients having recently undergone transcatheter aortic valve replacement (TAVR). Not recommended in patients receiving concomitant systemic treatment w/ azole-antimycotics (eg, ketoconazole) or HIV PIs (eg, ritonavir). Avoid in the treatment of ACS in patients w/ a prior stroke or TIA; avoid in combination w/ ASA in patients w/ previous haemorrhagic/ischemic or lacunar/non-lacunar stroke. Caution in patients w/ an increased bleeding risk eg, congenital or acquired bleeding disorders, uncontrolled severe arterial HTN, active ulcerative GI disease, recent GI ulcerations, vascular retinopathy, recent intracranial or intracerebral hemorrhage, intraspinal or intracerebral vascular abnormalities, recent brain, spinal or ophth surgery, bronchiectasis or history of pulmonary bleeding. Risk for development of an epidural or spinal hematoma when neuraxial (epidural/spinal) anesth or spinal puncture is performed patients treated w/ antithrombotics for prevention of thromboembolic complications. If an invasive procedure or surgical intervention is required, stop medication at least 12 hr (for 2.5 mg) & 24 hr (for 10 mg, 15 mg & 20 mg) before the intervention. Not recommended for patients w/ history of thrombosis who are diagnosed w/ antiphospholipid syndrome & are persistently triple +ve (for lupus anticoagulant, anticardiolipin antibodies & anti-β
2-glycoprotein I antibodies). Moderate to severe renal impairment. Lactose or galactose intolerance (eg, the Lapp lactase deficiency or glucose-galactose). May affect ability to drive or use machines. Use w/ effective contraception in women of childbearing potential. Childn & adolescent <18 yr.
10 mg: Patients undergoing hip fracture surgery.
10 mg, 15 mg & 20 mg: Not recommended as an alternative to unfractionated heparin in patients w/ pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy.
15 mg & 20 mg: Patients who undergo PCI w/ stent placement.